Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series

Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis

“…Clinical psoriasiform dermatitis developed in our patient after treatment with dupilumab for autoeczematization secondary to chronic stasis dermatitis. Similar events have been reported in patients with atopic dermatitis who developed psoriasiform dermatitis after treatment with dupilumab, but this is the first case related to autoeczematization [8][9][10][11][12].…”

Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports

“…7 Conversely, there have been reports of psoriasiform eruptions, psoriasis, and inflammatory arthritis developing after initiating dupilumab, which could indicate upregulation of Th1/ Th17 cytokines. 3,4,[8][9][10] The etiology of seborrhoeic dermatitis is multifactorial, involving the interaction between intrinsic susceptibility, immunological defects, and fungal colonization. 11 Introducing cytokine imbalances might influence the immune response to Malassezia, leading to the development of seborrhoeic dermatitis in susceptible patients.…”

“…New regional dermatoses affecting the face are increasingly being recognized as an adverse event to dupilumab; these can be challenging to diagnose and can lead to discontinuation of treatment. 3 Herein, we report two cases of patients presenting with new dermatoses while on dupilumab, and outline how these were managed successfully without discontinuation of their treatment.…”

Eczematous reaction to ixekizumab successfully treated with dupilumab

“…Recently, Burlando et al observed a case of atopic‐like dermatitis occurring after secukinumab injection (Burlando, Cozzani, Russo, & Parodi, ). To our knowledge, this is the first report of recurrence of AD in a patient treated with anti‐IL‐17 successfully cured with dupilumab, a fully human monoclonal antibody specifically preventing the signaling of IL‐4 and IL‐13 by inhibiting the IL‐4 receptor alpha subunit (Napolitano, Scalvenzi, et al, ). This drug has been evaluated for diseases that are implicated by Th2 pathways predominant with IL‐4 and IL‐13 such as moderate‐to‐severe AD, asthma, and chronic sinusitis and showed to be effective in terms of clinical outcome and patient‐reported symptoms of anxiety and health‐related quality of life (Le Floc'h et al, ).…”

“…Biological drugs can induce paradoxical reactions through the blockade of immunological targets as a result of a cytokine imbalance (Munera‐Campos, Ballesca, Richarz, Ferrandiz, & Carrascosa, ). We have recently described the possible occurrence of eczematous eruption (EE) during anti‐interleukin (IL)‐17 treatment of psoriasis (Napolitano et al, ) as well as psoriasiform eruption during dupilumab therapy for adult atopic dermatitis (AD) (Napolitano, Scalvenzi, Fabbrocini, Cinelli, & Patruno, ). Herein we report an EE (AD‐like) in a psoriasis patient receiving anti‐IL‐17 (ixekizumab) treatment completely cured with dupilumab.…”